Back

Influence of novel risk markers on defibrillator implantation in hypertrophic cardiomyopathy

29 August 2022 (14:15 - 15:00)
Organised by:
Congress Presentation Part of: Electrocardiography and cardiomyopathies Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Mr William Procter

Barts Health Trust, London (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Atrial fibrillation concerning worse prognosis in patients with left ventricular noncompaction
Doctor W. Xu (Beijing, CN)
Abstract Slides
Presentation thumbnail
Promise or peril : The ECG in HCM
Doctor H. Cronin (Cork, IE)
Abstract Slides
Presentation thumbnail
New-onset atrial fibrillation diagnosed by cardiac implantable devices in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis
Doctor V. Hurtado (Miami, US)
Abstract Slides
Presentation thumbnail
3 year outcomes of permanent pacemaker implantation after alcoholic septal ablation
Doctor A. Grazina (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Prognostic role of low QRS voltages in patients with cardiac amyloidosis
Associate Professor F. Guerra (Ancona, IT)
Abstract Slides

Access the full session

Session thumbnail
Electrocardiography and cardiomyopathies

The Event

Event poster

ESC Congress 2022

29 August 2022 14:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources